Raymond James initiates American Healthcare REIT stock at strong buy on Trilogy partnership

Raymond James has rated American Healthcare REIT (NYSE: AHR) as a Strong Buy, with a price target of $62.00. The investment firm credits the company's partnership with Trilogy as a significant factor in their positive assessment. AHR's stock is currently trading at $52.52, boasting a market capitalization of $12.25 billion and delivering a robust 29.8% return over the past year.

Analysts highlight AHR's ability to drive performance across its existing senior assets while maintaining a cost of capital that supports consolidation efforts. The firm points to the company's strong balance sheet and selective investments, forecasting continued near-term organic growth that may be further enhanced through acquisitions and development.

Raymond James emphasizes the importance of differentiation in the senior housing sector, crediting Trilogy as the key differentiator. The company has shown impressive growth, with a 16.9% revenue increase over the past year and a dividend yield of 3.81%. InvestingPro rates AHR's financial health as GREAT, though the analysis suggests the stock may be overvalued at current levels.

Notably, AHR reported a strong second-quarter 2026 performance, with normalized funds from operations (FFO) per share of $0.54, surpassing estimates. The company also revealed a substantial acquisition pipeline, with $2 billion in total closed investments and $675 million under contract. Other analysts, including KeyBanc and Citizens, have also expressed a positive outlook, with raised price targets and maintained Market Outperform ratings.